Ocular Microbiology and Immunology Group
Back to OMIG Main Page

2016 Agenda and Abstracts | < Previous | Next >

2016 OMIG Abstract 10

Release of Moxifloxacin from Corneal Collagen Shields
S Zhou, KM Hunt, AS Grewal, KM Brothers, DK Dhaliwal, RMQ Shanks
The Charles T Campbell Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Purpose: The objectives of this study are to investigate diffusion of moxifloxacin through bandage contact lenses (BCL) vs collagen shields (CS) and evaluate the relative ability of BCLs and CSs to absorb and release moxifloxacin over time, and estimate the potential of moxifloxacin release in the clinical setting.

Methods: Using an in vitro model, the diffusion of 5% moxifloxacin across BCLs and CSs were compared. Next, the amount of drug release from BCLs and CSs soaked in 0.5% moxifloxacin and Vigamox were measured. Finally, to simulate the clinical application, CSs were soaked in Vigamox and the total concentration released was detected. In each model, absorbance of solutions was measured using a spectrophotometer at set time points over up to a 24-hour period. The concentration of moxifloxacin was determined by comparing the experimental value with a standard curve.

Results: In the diffusion assay, 35.7 ± 10.5% diffused through the BCLs and 36.2 ± 11.8% diffused through the CSs (p=0.77). The absorption assay demonstrated at 120 min, a total of 33.3 ± 6.77µg/ml was released from BCLs compared to 45.8 ± 5.2 µg/ml from the CSs (p=0.0008). In vitro experiments to simulate clinical application of Vigamox soaked CS found the concentration of moxifloxacin released of 127.7 ± 7.25 µg/ml in 2mL PBS over 24 hours.  

Conclusions: Our study suggests that moxifloxacin is able to diffuse through BCLs and CSs at similar rates, however CSs have greater capacity to absorb and release moxifloxacin compared to BCLs. Furthermore, in the in vitro model, Vigamox soaked CSs released 250 µg of moxifloxacin, and may therefore be a useful method to prevent endophthalmitis in patients who are noncompliant with eye drops.

S=Research to Prevent Blindness, Eye and Ear Institute of Pittsburgh, NIH grant EY024785, NIH grant AI085570, NIH Core Grant EY08098, Collagen Shields were kindly donated by Oasis Medical.

2016 Agenda and Abstracts | < Previous | Next >